0000899243-18-013572.txt : 20180521 0000899243-18-013572.hdr.sgml : 20180521 20180521163625 ACCESSION NUMBER: 0000899243-18-013572 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180517 FILED AS OF DATE: 20180521 DATE AS OF CHANGE: 20180521 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Choi Jung CENTRAL INDEX KEY: 0001650126 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37539 FILM NUMBER: 18850116 MAIL ADDRESS: STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC. STREET 2: 400 EAST JAMIE COURT, SUITE 101 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc. CENTRAL INDEX KEY: 0001629137 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274825712 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650741-7700 MAIL ADDRESS: STREET 1: 171 OYSTER POINT BLVD, SUITE 300 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-05-17 0 0001629137 Global Blood Therapeutics, Inc. GBT 0001650126 Choi Jung C/O GLOBAL BLOOD THERAPEUTICS, INC. 171 OYSTER POINT BLVD., SUITE 300 SOUTH SAN FRANCISCO CA 94080 0 1 0 0 See Remarks Common Stock 2018-05-17 4 S 0 1600 48.25 D 136077 D Common Stock 2018-05-17 4 M 0 198 3.40 A 136275 D Common Stock 2018-05-17 4 M 0 601 3.40 A 136876 D Common Stock 2018-05-17 4 M 0 601 3.40 A 137477 D Common Stock 2018-05-17 4 S 0 1400 48.25 D 136077 D Common Stock 25000 I By Trust Stock Option (Right to Buy) 3.40 2018-05-17 4 M 0 198 0.00 D 2025-04-08 Common Stock 198 74964 D Stock Option (Right to Buy) 3.40 2018-05-17 4 M 0 601 0.00 D 2025-04-08 Common Stock 601 2675 D Stock Option (Right to Buy) 3.40 2018-05-17 4 M 0 601 0.00 D 2025-04-08 Common Stock 601 2675 D This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. These shares of Common Stock were subject to the Issuer's right of repurchase, which lapsed with respect to 25% of the shares on April 6, 2016 and in 12 equal quarterly installments thereafter. 25% of the shares subject to this option vested and became exercisable on April 6, 2016 and the remaining shares subject to this option shall vest and become exercisable in 12 equal quarterly installments thereafter. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On March 10, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. On April 9, 2015, the Reporting Person was granted an option to purchase 37,142 shares of Common Stock under the Issuer's 2012 Stock Option and Grant Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the Issuer's securities. On September 29, 2016, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 9,286 of the shares underlying such option. Chief Business and Strategy Officer Lesley Ann Calhoun, as Attorney-in-Fact 2018-05-21